Immutep Ownership
PRRUF Stock | USD 0.20 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Immutep |
Immutep Pink Sheet Ownership Analysis
About 24.0% of the company shares are owned by institutional investors. The book value of Immutep was at this time reported as 0.11. The company recorded a loss per share of 0.02. Immutep Limited had not issued any dividends in recent years. The entity had 1:10 split on the 5th of November 2019. Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia. Immutep operates under Biotechnology classification in the United States and is traded on OTC Exchange.The quote for Immutep Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Immutep Limited contact Marc Voigt at 61 2 8315 7003 or learn more at https://www.immutep.com.Currently Active Assets on Macroaxis
Other Information on Investing in Immutep Pink Sheet
Immutep financial ratios help investors to determine whether Immutep Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immutep with respect to the benefits of owning Immutep security.